LGC Clinical Diagnostics’ Post

𝐍𝐄𝐖 𝐏𝐑𝐎𝐃𝐔𝐂𝐓 🎉 𝐕𝐀𝐋𝐈𝐃𝐀𝐓𝐄® 𝐌𝐓𝐗 is now available for Roche cobas®! This is a brand new addition to our Therapeutic Drug Monitoring class! VALIDATE® MTX offers Methotrexate (MTX) for easy, fast, efficient calibration verification and linearity testing. 𝐖𝐡𝐲 𝐌𝐞𝐭𝐡𝐨𝐭𝐫𝐞𝐱𝐚𝐭𝐞? Methotrexate is an antineoplastic drug that is used in the treatment of Psoriasis, Rheumatoid Arthritis, and other autoimmune conditions. It works by decreasing inflammation, which can reduce pain and prevent long-term injury to the joints and skin. It may also be used to treat some types of cancer (i.e. non-Hodgkin Lymphomas, Osteosarcoma) It works by slowing down the growth of cancer cells. Methotrexate is extremely potent and levels are monitored to assess toxicity. 𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞: https://hubs.ly/Q02_17-Y0 #Methotrexate #TherapeuticDrugMonitoring #CalibrationVerification #ClinicalDiagnostics

Anti-tumor necrosis factor-alpha (TNF-α) therapies have revolutionized clinical care, offering hope to patients with conditions like rheumatoid arthritis, Crohn's disease, and more. Learn about the historical development and future potential of these therapies, including their role in treating COVID-19 and certain types of cancer. Read the full article: https://lnkd.in/eACFxxii #AutoimmuneDiseases #MedicalAdvancements #TNFTherapies 🩺💊 #Anogen

" Product of the Day : ZELGOR 500MG & MABURA 40MG/0.8ML Injection " ZELGOR 500MG is used in cancer treatment to inhibit tumor growth, while MABURA 40MG/0.8ML is primarily used in the treatment of rheumatoid arthritis, ankylosing spondylitis, juvenile idiopathic arthritis, plaque psoriasis, and psoriatic arthritis. Together, they offer targeted therapy, improving treatment outcomes for cancer patients with advanced care needs. DM Sayar Life-Care to buy Quality medicines ! 😊 #injections #syringes #tablets #oncologist #criticalcare #pharmaceuticals #exporterworldwide #rheumatoidarthritis #psoriaticarthritis #medicines [ZELGOR oncology treatment, MABURA injection for critical care, ZELGOR targeted cancer therapy]

Bemarituzumab is a humanized monoclonal antibody that is selective for FGFR2b. Learn how the addition of #bemarituzumab to mFOLFOX6 can result in longer PFS and OS rates compared with mFOLFOX6 alone in patients with FGFR2b-positive advanced #gastriccancer:

Tharolax® 500mg Capsule is used in the treatment of some kinds of #cancer and to prevent painful episodes associated with sickle cell anemia. 📝 #HydroxyureaCapsule 500mg,#TajPharma, 10 X 10 Capsules. It can be used by itself or in combination with other anticancer medications and radiation, depending on the type of cancer. Although hydroxyurea (Tharolax®) is available as a convenient oral medication, it has serious risks like low blood cell counts that can lead to infections and bleeding. Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928.5 It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. #Hydroxyurea #Hydrea #CML Join us on our journey!🌐 🌍 📧: [email protected]🌻

I NEM 1GM Injection combines imipenem and cilastatin, effective against severe infections. CAMPTO 100MG Injection, containing irinotecan, treats advanced colorectal cancer by inhibiting cancer cell growth. Both medications are administered under medical supervision, ensuring safety and efficacy in treatment protocols. Dm Sayar Life-Care to buy medicines at Best prices ! 😍 #inem #injections #productoftheday #infectioncontrol #chemotherapy #medicalproducts #colorectal #irinotecan [Colorectal Cancer Management, Severe Bacterial Infections Treatment, Irinotecan Chemotherapy, Imipenem Cilastatin Injection, Oncology Injectable Drugs]

Inhibition of colorectal cancer by a natural biomaterial and it's interaction with serum albumins... Drug with very low side effect... My 12th paper #colorectalcancer #naturalproduct #invitro #spectroscopicanalysis #hsa #bsa #proteins #peptides #drugdiscovery #drugdesign #circulardichroism #isothermaltitrationcalorimetry #mttassay #antiproliperativeactivity #AOEtBr #fluorescence #uv #quenchingstudy #EGFR

Patients With Type 2 Diabetes Taking GLP-1 Treatments Have Lower Risk Of Developing Obesity-Related Cancers, Study Suggests Reuters (7/5, Fick) reported, “Patients with type 2 diabetes taking GLP-1 treatments, which include Ozempic [semaglutide], have a lower chance of developing 10 types of obesity-related cancers than those taking insulin and other diabetes drugs, according to a study published on Friday.” The study’s “findings are ‘preliminary evidence of the potential benefit’ of GLP-1 drugs for cancer prevention in high-risk [populations], the researchers concluded.” The findings were published in JAMA Network Open. https://buff.ly/3Lm9lz7

The latest in ACP #Gastroenterology Monthly: http://ow.ly/EneC50HcMkX 🔸 IV iron appears safe, effective for bleeding-related iron-deficiency anemia in cirrhosis 🔸 GLP-1s associated with lower risk of hepatic decompensation than other diabetes drugs 🔸 Colectomy linked with greater risk of AKI, kidney failure in patients with IBD 🔸 Spotlight on colorectal cancer screening intervals

The Prelude team was in San Diego this week for the American Society of Hematology (ASH) Annual Meeting, where we shared the first interim clinical data from our ongoing open-label, dose-escalation trial of PRT2527, our potent and highly selective CDK9 inhibitor. “CDK9 has long been considered a potential therapeutic approach for treating hematologic malignancies and a highly selective CDK9 inhibitor was sought to minimize off target toxicity,” says Jane Huang, M.D., Prelude's President and Chief Medical Officer. “We are encouraged by the results demonstrated to date by PRT2527 both as a monotherapy and particularly in combination with zanubrutinib resulting in an overall response rate of 38.5% including two patients with aggressive lymphomas who had received prior CAR-T therapy. These results represent a positive step for CDK9 inhibition as a possible future therapeutic approach for patients with aggressive hematologic cancers with limited treatment options.” For details, see our press release below or visit our website at preludetx.com. #ASH24 #precisiononcology #Cancerresearch